ivermectin

Ivermectin as a Context-Dependent Immunomodulator: What the Evidence Actually Shows

Photo by National Institute of Allergy and Infectious Diseases / Unsplash

Nov 14, 2026 · @Yoon Hang Kim MD

Abstract

Ivermectin produces measurable immunological effects in experimental systems, but whether those effects translate into clinically meaningful immunomodulation at tolerable human exposures remains unresolved. In cell and animal models, ivermectin has been reported to suppress NF-κB/MAPK inflammatory signaling, shift the Th17–Treg balance toward regulatory phenotypes via IL-2/STAT5, and modulate ATP–P2X4/P2X7 purinergic signaling — yet other work reports NF-κB activation, oxidative stress, and macrophage immunotoxicity, so the experimental response is not uniformly anti-inflammatory. Human immune-profiling studies at conventional doses, including a healthy-volunteer study and a 2026 mild-COVID cohort, have not demonstrated significant systemic immunomodulation. This review distinguishes experimental observations from causal mechanisms and from clinical effectiveness, notes an integrity correction affecting a key oncology citation, and outlines the exposure-response evidence needed before ivermectin could be considered a validated systemic immunomodulatory treatment. Ivermectin is not an established therapy for autoimmune disease, cancer, or viral inflammatory conditions.

About Dr. Kim

Yoon Hang Kim MD is board-certified in Preventive Medicine and practices integrative and functional medicine. He has authored multiple books and more than 25 peer-reviewed articles, founded the LDN Support Group, and completed a University of Arizona Osher Fellowship under Dr. Andrew Weil. His prior roles include Medical Director of Integrative Oncology at Miami Cancer Institute and Director of the Integrative Medicine Program at the University of Kansas Medical Center. He holds UCLA medical acupuncture certification and is a recipient of the Institute for Functional Medicine (IFM) Scholarship. His work focuses on translating mechanistic science into careful, evidence-informed clinical judgment — the lens this review is written through.

Ivermectin is an established antiparasitic medication with experimental effects that extend beyond its conventional pharmacology. Laboratory and animal studies have reported changes in inflammatory signaling, T-cell differentiation, purinergic signaling, and immune-cell function. These findings raise legitimate questions about its immunomodulatory properties — but the evidence is neither uniformly anti-inflammatory nor consistently immunostimulatory.

Depending on experimental conditions, ivermectin has been associated with suppression of inflammatory signaling, shifts in regulatory T-cell populations, and — in other settings — increased inflammatory activity and direct cellular toxicity. This variability is scientifically interesting, but it should not be read as evidence that ivermectin selectively restores immune balance.

A further limitation is the substantial gap between experimental conditions and clinically achievable human exposure. Human immune-profiling studies have generally failed to demonstrate meaningful systemic immunomodulation at conventional doses. Whether different dosing strategies or disease-specific environments could produce clinically meaningful effects remains unresolved.

This review evaluates the principal proposed mechanisms, distinguishes experimental observations from causal hypotheses, examines the limitations of the human data, and identifies what evidence would be needed before ivermectin could be considered a validated systemic immunomodulatory treatment — so clinicians can speak to this topic accurately, without overclaiming or reflexively dismissing legitimate science.

Innate Immunity: Dampening Inflammatory Signaling

The most straightforward hypothesis is that ivermectin reduces inflammatory mediator production by interfering with signaling downstream of inflammatory stimulation.

NF-κB Pathway

In a 2008 study, Zhang and colleagues examined LPS-stimulated murine macrophages and an LPS-challenged mouse model. Ivermectin reduced TNF-α, IL-1β, and IL-6 production, suppressed nuclear translocation of the NF-κB p65 subunit, and improved survival in mice exposed to a lethal LPS challenge. The proposed mechanism is that ivermectin interrupts the inflammatory cascade at or upstream of NF-κB nuclear translocation. This demonstrates a pathway association — not proof that ivermectin directly binds or antagonizes TLR4. Zhang et al., Inflamm Res 2008 (PMID 19109745)

MAPK Pathway

A subsequent macrophage study found that ivermectin suppressed phosphorylation of p38, ERK1/2, and JNK — the three major arms of the MAPK network — with reduced iNOS and COX-2 expression and lower nitric oxide and prostaglandin E2 production. Read together with the NF-κB data, this suggests ivermectin may reduce both cytokine transcription and downstream inflammatory effector production in these models. PMID 19168156

Evidence of Opposing Innate Immune Effects

The anti-inflammatory picture is not the whole story, and this is important for an honest account. A separate study — Immunotoxicity Induced by Ivermectin Is Associated with NF-κB Signaling Pathway on Macrophages (Ping Zhang et al., Chemosphere) — reported the opposite direction: activation of NF-κB signaling, overproduction of reactive oxygen species, cytochrome C release, DNA double-strand damage, and reduced macrophage viability and function. Zhang P et al., Chemosphere (PMID 34843829)

This matters for two reasons. First, it reinforces the central thesis: the experimental innate-immune response to ivermectin is not consistently anti-inflammatory and depends heavily on exposure conditions. Second, it introduces a critical interpretive caution — a decrease in inflammatory cytokines is not necessarily beneficial if it reflects impaired cellular viability rather than regulated signaling. Therapeutic immune modulation and direct cellular toxicity can both lower measured cytokines, and they are not the same thing.

Adaptive Immunity: Shifting the Th17–Treg Balance

For autoimmune disease, the most directly relevant study is Xie et al. (2023), which used a mouse model of autoimmune CNS inflammation (experimental autoimmune encephalomyelitis). Xie et al., Inflammation 2023;46:1626–1638

The investigators reported a coherent set of findings:

Reduced Th1/Th17 responses and lower IFN-γ/IL-17A production (less pathogenic inflammatory T-cell activity).
Increased IL-2 production and CD25 expression (greater activity of the axis that supports regulatory T cells).
Increased CD4+CD25+Foxp3+ Tregs (a measurable shift toward regulatory representation).
Increased STAT5 phosphorylation (a possible link between IL-2 signaling and the observed T-cell shift).
Reduced CNS inflammatory infiltration and clinical disease scores (functional benefit within the model).

Together these support an IL-2/STAT5 hypothesis: under these particular autoimmune conditions, ivermectin produced an immune phenotype consistent with increased regulatory T-cell activity.

Two cautions are worth stating plainly. First, increased STAT5 phosphorylation accompanying Treg expansion does not prove that IL-2/STAT5 is the necessary causal pathway; establishing causation would require blocking or disrupting that signaling and showing the effect disappears. The authors themselves describe it as a possible partial mediator, not an established target. Second, the finding was observed in one experimental model and should not be generalized to autoimmune disease broadly.

Dose is a major translational limitation. The paper used a 10 mg/kg mouse regimen, which cannot be read as a human treatment dose or compared directly with human mg/kg dosing without accounting for species-specific pharmacokinetics, protein binding, and tissue penetration. Simple body-weight conversion between mouse and human is not valid here.

Purinergic Signaling: A Proposed Explanation for Divergent Effects

Ivermectin's interaction with the ATP–P2X4/P2X7 signaling axis has been proposed as an explanation for its apparently divergent immune effects across settings.

Preclinical breast cancer research reported that ivermectin, acting as an allosteric modulator of the ATP/P2X4/P2X7 axis, induced immunogenic cancer-cell death, increased tumor T-cell infiltration, and preferentially affected immunosuppressive myeloid populations and Tregs — yielding an increased effector-T-cell/Treg ratio, the opposite direction from the Treg increase reported in the autoimmune model above. Draganov et al., npj Breast Cancer 2021

An integrity note is required here. This paper received an Author Correction in February 2026: errors were identified in Figure 4 panels D and F, the original data were no longer available to replace the incorrect images, and the affected images were blocked out. The authors state that the overall results and conclusions are unchanged. This does not invalidate the mechanistic hypothesis, but it does reduce the weight the paper can bear as a foundation for clinical conclusions, and independent replication is needed before these observations support any clinical claim. Author Correction, npj Breast Cancer 2026;12:31

Treated cautiously, the purinergic framework is still useful. The two contexts differ in a way that may explain the divergent results without appealing to any unifying intelligence in the drug:

In autoimmune tissue: the observed effect favored regulatory responses and reduced pathogenic T-cell inflammation.
In the tumor microenvironment: ATP-rich local conditions and differential immune-cell sensitivity were associated with immunogenic cell death and reduced local immune suppression.

The better interpretation is heterogeneity, not homeostasis. Different cell populations have different receptor expression, signaling networks, inflammatory states, and pharmacological sensitivities, so the same compound can push Tregs up in one system and down in another. That is a demonstration of context-dependence — not evidence that ivermectin recognizes what a tissue needs and supplies the "correct" immune response. There is no support for that stronger, teleological claim, and clinicians should be wary of it when they encounter it in popular writing on this topic.

The Cholinergic Hypothesis: Interesting but Early

A 2025 article in Medical Hypotheses ("Cholinergic eubiosis") proposes that ivermectin enhances the cholinergic anti-inflammatory pathway and thereby influences intestinal immunity and barrier integrity. Medical Hypotheses 2025

This is explicitly a proposed hypothesis, not a demonstrated clinical mechanism, and it should be ranked below the directly measured NF-κB/MAPK and T-cell findings above. Its proposed effects on gut immunity should not be presented as established treatment effects. For clinicians who think in terms of gut-barrier function and the gut–immune axis it offers a conceptual bridge — but a conceptual one only, pending experimental support.

What Human Studies Actually Show

The central question is not whether ivermectin can alter immune biology experimentally — it clearly can under the right conditions — but whether a tolerable human exposure produces a clinically meaningful effect.

Healthy-Volunteer Study

Wilson and colleagues gave healthy volunteers a single 0.15 mg/kg dose and evaluated blood counts, 41 cytokines and chemokines, and expression of 770 myeloid-related genes. They found no significant changes in blood counts or circulating cytokines, only three differentially expressed genes at four hours (none significant at 24 hours), and no improvement in leukocyte killing of Brugia malayi microfilariae ex vivo. Wilson et al. (PMID 34090504)

This argues against a large, immediate systemic immune effect at the standard antiparasitic dose in healthy people. It does not exclude tissue-specific effects, effects in a different disease state, or effects of repeated exposure — but it does set a baseline: at this dose, the effect is not visible in blood.

COVID-19 Immune-Profiling Study (2026)

A more recent study of 24 patients with mild COVID-19 examined immune responses and transcriptional profiles over 28 days. Investigators observed only weak differences and concluded that the findings did not support significant immunomodulatory effects likely to benefit disease progression. Scientific Reports 2026

Its small size and narrow disease setting (mild COVID only) limit generalization — but it is the most direct test of the COVID-specific immunomodulation hypothesis, and the result is underwhelming.

Taken together

These studies temper the preclinical enthusiasm without erasing it. The mechanistic biology is real. What has not been shown is that the biology occurs at achievable human tissue concentrations — and so far it has not been demonstrated convincingly.

The Translational Gap: Pharmacokinetics and Its Limits

The disconnect between positive preclinical findings and limited human immune effects is often attributed to pharmacokinetics, and that is a leading candidate — but it is not the only possible explanation, and it should not be presented as settled.

The in vitro macrophage studies used concentrations achievable in culture. The mouse autoimmune model used 10 mg/kg, which cannot be scaled to humans by simple weight conversion. It is plausible that matching an immune-relevant tissue concentration in humans would require exposures beyond what is currently approved. But two cautions apply: a negative human study does not prove the concentration was inadequate — it establishes that the specified dose and endpoints did not produce the measured effect; and a high effective mouse dose does not establish that a pharmacologically effective human exposure would necessarily be unsafe.

Other explanations also remain live: differences in disease biology, immune-cell populations, experimental endpoints, model validity, and nonspecific effects at high concentrations.

Rather than assume pharmacokinetics is the answer, it is more useful to separate three distinct, still-unresolved questions:

Achievability — Are the relevant experimental concentrations achievable in human tissue at tolerable doses?
Target engagement — Do those concentrations engage the same molecular pathways in human tissues that they engage in the models?
Clinical benefit — Does target engagement produce a clinically meaningful benefit with an acceptable safety margin?

All three remain open for the proposed systemic immunomodulatory indications. The most informative next study would connect measured drug exposure (plasma Cmax and free-drug levels) to target engagement and immune phenotype — stimulated NF-κB activity, STAT5 phosphorylation, Th17/Treg proportions, and functional cytokine responses — rather than inferring immunomodulation from symptom change. Quantitative exposure comparisons, not qualitative statements about "high doses," are what this field needs next.

Exposure, Duration, and Safety

Ivermectin has a well-established safety profile when used appropriately for approved antiparasitic indications, typically as single or intermittent doses. That experience cannot be assumed to generalize to the repeated, prolonged, or substantially higher exposures that systemic immunomodulation for chronic inflammatory disease or oncology would require.

FDA prescribing information and pharmacovigilance reports identify potential neurological toxicity — including confusion, ataxia, seizures, and severe alterations in consciousness — particularly with high exposure or impaired CNS barrier function. Drug interactions (notably with other P-glycoprotein substrates and CNS-active agents) and exposure-related risks also deserve consideration before any off-label, higher-dose, or prolonged use. The immunotoxicity and cytotoxicity data discussed earlier are a reminder that higher concentrations are not biologically free.

To state it plainly: ivermectin is not an established treatment for autoimmune disease or cancer. Nothing in the mechanistic literature changes that, and it should not replace effective, disease-directed treatment. Any exploration of immunomodulatory use belongs in properly designed clinical trials with exposure monitoring, not in routine practice.

Clinical Implications: How to Talk About This Honestly

For clinicians evaluating ivermectin's immune-modulating potential — in COVID-19, autoimmune disease, or integrative oncology — it helps to separate three levels of evidence and keep the mechanistic certainty calibrated to each.

Proposition	Confidence
Ivermectin can alter immune signaling in experimental systems	High
Its observed immune effects vary across experimental conditions	Moderate to high
These properties produce predictable, beneficial immune modulation in humans	Not established

What can be said with confidence: Ivermectin has shown immunomodulatory activity in cell and animal models through several mechanisms — NF-κB/MAPK modulation (in both directions), Th17–Treg shifts consistent with IL-2/STAT5 activity, and purinergic (P2X4/P2X7) effects. These effects are context-dependent, not unidirectional, and are best explained by cellular heterogeneity rather than any homeostatic property of the drug.

What requires qualification: Human studies at standard dosing have not demonstrated significant systemic immunomodulation. The pharmacokinetic bridge between effective preclinical concentrations and achievable human tissue exposure has not been built. Key supporting oncology data carry a published correction, and some innate-immune data point toward immunotoxicity rather than benefit.

A critical distinction — biomarkers are not outcomes. Even demonstrating the proposed biomarker changes would not establish clinical effectiveness. Decreased IL-6 does not mean improved autoimmune disease; increased Tregs do not mean better patient outcomes; improved tumor immune infiltration does not mean reduced cancer mortality. A credible program must connect pharmacokinetics to target engagement, to functional immune change, and finally to validated, disease-specific clinical outcomes. This is especially important in integrative oncology, where a compelling mechanistic signal is not the same as patient benefit.

Scope of the current conclusion: Controlled human studies have not established clinically meaningful systemic immunomodulation as an independent therapeutic mechanism for ivermectin in autoimmune disease, cancer, or viral inflammatory conditions. (This is a statement about systemic immunomodulation for non-parasitic disease; it does not bear on ivermectin's established antiparasitic efficacy.)

Conclusion

The strongest contribution of this literature is a single, defensible proposition: ivermectin is a pharmacologically complex compound whose experimental immunological actions vary by context, rather than a drug that can be classified simply as an anti-inflammatory or an immune stimulant. That is a worthwhile scientific discussion — and a more accurate one than either the enthusiastic or the dismissive framings that dominate public conversation.

But the evidence supports this as a critical mechanistic review, not as a basis for clinical use. Ivermectin can alter immune signaling in experimental systems (high confidence); those effects vary across conditions (moderate-to-high confidence); and whether they produce predictable, beneficial immune modulation in humans is not established. The honest position holds all three at once.

For anyone designing the next study, the task is clear: measure drug exposure, demonstrate target engagement in human tissue, show functional immune change, and tie it to validated clinical outcomes with an acceptable safety margin. Until that chain is built, the mechanism is plausible, the biology is real, and the clinical application remains unproven.

Sources

Work with Dr. Kim

Yoon Hang Kim MD offers membership-based, insurance-free integrative and functional medicine through telemedicine, serving a limited panel of patients across Iowa, Illinois, Missouri, Georgia, Florida, and Texas. The focus is personalized, evidence-informed care — taking the time to understand root causes and build a plan around the whole person.

To learn more or inquire about membership, visit directintegrative.com.

This article is for professional and educational purposes only. It is not medical advice and does not establish a physician–patient relationship. Ivermectin is not an FDA-approved treatment for autoimmune disease, cancer, or viral inflammatory conditions, and nothing here should be taken as a recommendation to use it for those purposes.